Michael Geffner is a seasoned physician-scientist with more than two decades of experience in clinical development and medical affairs within the biotechnology sector, specializing in autoimmune and inflammatory diseases. Before joining Immunovant, he held senior leadership roles at several pharmaceutical companies, where he directed clinical trial programs that advanced novel immunomodulatory therapies from early-phase studies through regulatory approval. His work has contributed to multiple peer-reviewed publications and has helped shape treatment paradigms for conditions such as rheumatoid arthritis and lupus. As Former Chief Medical Officer at IMMUNOVANT INC., Geffner oversaw the company’s global clinical strategy, medical governance, and regulatory interactions for its pipeline of FcRn-targeted therapies. He played a central role in designing and executing pivotal trials that evaluated the safety and efficacy of investigational treatments for Graves’ disease and other autoimmune disorders, ensuring rigorous adherence to ethical and scientific standards. His leadership helped position Immunovant as a leader in next-generation immunology therapeutics. Geffner’s career reflects a deep commitment to translating scientific innovation into meaningful patient outcomes, underscored by his board certifications in internal medicine and rheumatology as well as his prior academic appointments. His contributions have been recognized through industry awards and invitations to speak at major medical conferences.